There hadn’t been a major diagnostic advance for preeclampsia – a potentially life-threatening high blood pressure condition that develops in 5 to 7% of all pregnancies and disproportionately affects Black women – in over a century. But in May, the FDA cleared two tests developed by Thermo Fisher Scientific that, based on the concentration of certain biomarkers in the patient’s blood, can quickly predict whether a pregnant person hospitalized with hypertension will develop severe preeclampsia within the next two weeks. “It’s changing the way that clinicians are able to get an objective reading and then make a decision” to prioritize treatment or discharge the patient, says Tina Liedtky, president of Thermo Fisher Scientific’s clinical diagnostics division.
- Taylor Swift Is TIME's 2023 Person of the Year
- Meet the Nation Builders
- Why Cell Phone Reception Is Getting Worse
- Column: It's Time to Scrap the Abraham Accords
- Israeli Family Celebrates Release of Hostage Grandmother
- In a New Movie, Beyoncé Finds Freedom
- The Top 100 Photos of 2023
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time